Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 272,049 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 272,049 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $20.06, for a total value of $5,457,302.94. Following the completion of the transaction, the director owned 14,561 shares of the company’s stock, valued at approximately $292,093.66. This represents a 94.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Up 2.4%

DYN stock opened at $19.67 on Thursday. The company has a quick ratio of 22.25, a current ratio of 22.25 and a debt-to-equity ratio of 0.15. The business has a 50 day moving average price of $17.58 and a two-hundred day moving average price of $18.36. The company has a market cap of $3.25 billion, a price-to-earnings ratio of -5.56 and a beta of 1.29. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). Analysts anticipate that Dyne Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Morgan Stanley decreased their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Chardan Capital reiterated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. JPMorgan Chase & Co. reduced their target price on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, HC Wainwright reduced their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.14.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in DYN. AQR Capital Management LLC bought a new position in shares of Dyne Therapeutics during the 1st quarter worth approximately $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Dyne Therapeutics by 5.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after acquiring an additional 2,886 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Dyne Therapeutics by 58.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after purchasing an additional 366,183 shares during the last quarter. Caxton Associates LLP acquired a new stake in Dyne Therapeutics during the 1st quarter worth approximately $157,000. Finally, Creative Planning lifted its holdings in Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock worth $138,000 after purchasing an additional 2,797 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.